{"transactions":[{"id":2604919,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":136324,"kind":"person","name":"Moxham Christopher","position":1,"cik":"0001843784","reported_name":"Moxham Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-12T20:20:57.000Z","date":"2021-08-10","kind":"exercise","acquired":false,"shares":31071,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option are scheduled to vest 25% on the first anniversary of the vesting commencement date of January 22, 2020. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service."}],"balance_after":72501,"derivative":{"exercise_price":7.84,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":31071},"source":{"system":"sec-edgar","filing":"0000899243-21-032755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924321032755/doc4.xml","form_type":"4"}},{"id":2604918,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":136324,"kind":"person","name":"Moxham Christopher","position":1,"cik":"0001843784","reported_name":"Moxham Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-12T20:20:57.000Z","date":"2021-08-10","kind":"exercise","acquired":false,"shares":20714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the option are scheduled to vest 25% on the first anniversary of the vesting commencement date of January 22, 2020. The remainder of the shares underlying the grant shall vest in equal quarterly installments over the following three years until the fourth anniversary of the vesting commencement date, subject to continued service."}],"balance_after":103572,"derivative":{"exercise_price":7.84,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":20714},"source":{"system":"sec-edgar","filing":"0000899243-21-032755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924321032755/doc4.xml","form_type":"4"}},{"id":2604917,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":136324,"kind":"person","name":"Moxham Christopher","position":1,"cik":"0001843784","reported_name":"Moxham Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stockm","published_at":"2021-08-12T20:20:57.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":31071,"price":18,"value":559278.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-032755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924321032755/doc4.xml","form_type":"4"}},{"id":2604916,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":136324,"kind":"person","name":"Moxham Christopher","position":1,"cik":"0001843784","reported_name":"Moxham Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-12T20:20:57.000Z","date":"2021-08-10","kind":"exercise","acquired":true,"shares":31071,"price":7.84,"value":243596.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 28, 2021."}],"balance_after":31071,"source":{"system":"sec-edgar","filing":"0000899243-21-032755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924321032755/doc4.xml","form_type":"4"}},{"id":2604915,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":136324,"kind":"person","name":"Moxham Christopher","position":1,"cik":"0001843784","reported_name":"Moxham Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-12T20:20:57.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":20714,"price":17,"value":352138.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-032755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924321032755/doc4.xml","form_type":"4"}},{"id":2604914,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":136324,"kind":"person","name":"Moxham Christopher","position":1,"cik":"0001843784","reported_name":"Moxham Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-12T20:20:57.000Z","date":"2021-08-10","kind":"exercise","acquired":true,"shares":20714,"price":7.84,"value":162397.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 10, 2020."}],"balance_after":20714,"source":{"system":"sec-edgar","filing":"0000899243-21-032755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924321032755/doc4.xml","form_type":"4"}},{"id":2868412,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":136324,"kind":"person","name":"Moxham Christopher","position":1,"cik":"0001843784","reported_name":"Moxham Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-10T21:30:21.000Z","date":"2021-02-08","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 8, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of February 6, 2021, subject to continued service."}],"balance_after":100000,"derivative":{"exercise_price":12.6,"expiration_date":"2031-02-07","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-21-005666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680581/000089924321005666/doc4.xml","form_type":"4"}}]}